• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2001 Fiscal Year Final Research Report Summary

Immunological control of the ovarian cancer using peptide and establishment of the monitoring method of the immunity cancer patient

Research Project

Project/Area Number 12671593
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Obstetrics and gynecology
Research InstitutionMie University

Principal Investigator

OKUGAWA Toshiharu  Mie University, Faculty of Medicine, Research Associate, 医学部, 助手 (90262998)

Co-Investigator(Kenkyū-buntansha) NIWA Masayuki  Mie University, Faculty of Medicine, Research Associate, 医学部・附属病院, 助手 (70293793)
SUGIYAMA Takashi  Mie University, Faculty of Medicine, Research Associate, 医学部・附属病院, 助手 (10263005)
YANOH Kenji  Mie University, Faculty of Medicine, Assistant Professor, 医学部, 講師 (80301224)
Project Period (FY) 2000 – 2001
Keywordstumor immunology / cancer peptide antigen / cancer vaccine / ovarian cancer
Research Abstract

Phase I clinical trials of cancer vaccine with human HER2 devived peptide HER2p63-71 were performed for the purpose of the safety of the peptide. (Method) Peptide vaccination began from amount 30 ug cohort that was increased to 100 μg, 300 μg, and 1 mg, were performed total 5 times subcutaneous injection. The 4th time and 5th GM-CSF were used together. (Result) 10 patients of HER2 positive ovarian cancer, breast cancer, and lung cancer, were registered, the detrimental phenomenon was not accepted in the cancer vaccine clinical test. The delayed-type Hypersensitivity was observed during the peptide vaccine for one patient, and became a positivity during after a test end continuation of peptide vaccine for one patient. The neoplasm reduction effect has not observed clinically, either. The HER2 p63-71 specific CD8+ Tlymphocyte was detected in the fluid in the thoracic cavity lymphocytes by one of breast cancer patients. The cancer vaccine using HER2 devived peptide accepts a detrimental phenomenon and was safe. The HER2p63-71 specific T-lynphocytes have been quantitatively measured by ELISPOT assay. Moreover, using of tetramer assay, detection of HER2p63-71 specific CTL was possible.

  • Research Products

    (8 results)

All Other

All Publications (8 results)

  • [Publications] Ikuta.Y et al.: "Presentation of a major histocompatibility complex class I-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex : implications for a polyvalent immuno-cell therapy"Blood. 99. 3717-3724 (2002)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Okugawa T. et al.: "A novel human HER2-derped peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals"European Journal of Immunology. 30. 3338-3346 (2000)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Shiku H. et al.: "Development of a cancer vaccine : peptides, proteins, and DNA"Cancer Chemotherapy and Pharmacology. 46. 77-82 (2000)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Ikuta.K et al.: "A HER2/NEU-derived peptide a k(d)-restricted imurine tumor rejection antigen, induces HER2-specitic HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes"International Journal of Cancer. 87. 553-558 (2000)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Ikuta Y. et al: "Presentation of a major histocompatibility complex class I-binding peptide by monocyte-derived denduth cells incorporating Hydrophobized polysaccharide-truncated HER2 protein complex ; implications for a polyvalent immuno-cell therory"Blood. 99. 3717-3724 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Okugawa T. et al: "Anovel human ER2-derived peptide homologous to the mouse k(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals"European Journal of Immundogy. 30. 3338-3346 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Shiku H. et al: "Development of a cancer vaccine : peptidas, proteins, and DNA"Cancer Chemotherapy and Phacmacology. 46. 77-82 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Ikuta Y. et al: "A HER2/NEU-derived peptide, a k(d)-restricted marine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes"International Journal of Cancer. 87. 553-558 (2000)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 2003-09-17  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi